This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Oncology, Nuclear medicine, PET-CT, Biopsy, Sampling, Tissue characterisation, Neoplasia
Authors:
S. Brocchi, A. Cappelli, C. Mosconi, M. Renzulli, F. Modestino, C. Nanni, T. Balbi, S. Fanti, R. Golfieri; Bologna/IT
DOI:
10.1594/ecr2016/B-1231
References
1.
Issakov J,
Flusser G,
Kollender Y,
et al.
Computed tomography-guided core needle biopsy for bone and soft tissue tumors.
Isr Med Assoc J 2003;5:28-30.
2.
Kiatisevi P,
Thanakit V,
Sukunthanak B,
et al.
Computed tomography-guided core needle biopsy versus incisional biopsy in diagnosing muscoloskeletal lesions.
J Orthop Surg 2013;21:204-208.
3.
Bomanji JB,
Costa DC,
Ell PJ.
Clinical role of positron emission tomography in oncology.
Lancet Oncol 2001;2:157–164.
4. Hustinx R,
Bénard F,
Alavi A.
Whole-body FDG-PET imaging in the management of patients with cancer.
Semin Nucl Med 2002;32:35–46.
5.
Cerci JJ,
Tabacchi E,
Bogoni M.
Fluorodeoxyglucose-PET/ Computed Tomography–Guided Biopsy PET Clin 2016;11:57–64.
6.
Nanni C,
Gasbarrini A,
Cappelli A,
et al. FDG PET/CT for bone and soft-tissue biopsy Eur J Nucl Med Mol Imaging 2015;42:1333–1334.